{"id":"diphenylcyclopropenone-dpcp","safety":{"commonSideEffects":[{"rate":null,"effect":"Contact dermatitis / localized eczema"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Lymphadenopathy"}]},"_chembl":{"chemblId":"CHEMBL1373467","moleculeType":"Small molecule","molecularWeight":"206.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DPCP works by inducing a controlled allergic contact dermatitis on the scalp, which activates T-cell mediated immunity and shifts the hair cycle from telogen (resting) back to anagen (growth) phase. The mechanism is thought to involve local immune activation that suppresses the autoimmune attack on hair follicles in alopecia areata, or directly stimulates follicle activity through inflammatory signaling.","oneSentence":"Diphenylcyclopropenone (DPCP) is a contact sensitizer that triggers a delayed-type hypersensitivity reaction to stimulate immune-mediated hair growth in alopecia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:42.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alopecia areata"}]},"trialDetails":[{"nctId":"NCT05481658","phase":"PHASE1","title":"Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases","status":"RECRUITING","sponsor":"Nicholas Gulati","startDate":"2022-10-06","conditions":"Cutaneous Metastases","enrollment":100},{"nctId":"NCT03651752","phase":"PHASE3","title":"DPCP for the Treatment of Alopecia Areata","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2024-04-01","conditions":"Alopecia Areata","enrollment":4},{"nctId":"NCT05020496","phase":"EARLY_PHASE1","title":"Trem-1 and Ultraviolet Radiation-induced Immune Suppression","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-03-21","conditions":"Skin Diseases","enrollment":70},{"nctId":"NCT05438290","phase":"PHASE1","title":"DPCP to Treat Cutaneous Neurofibromas Associated With NF1","status":"COMPLETED","sponsor":"Nicholas Gulati","startDate":"2022-09-14","conditions":"Cutaneous Neurofibroma","enrollment":17},{"nctId":"NCT04775979","phase":"PHASE4","title":"Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-01-17","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT03625219","phase":"NA","title":"Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2018-07-26","conditions":"Delayed Type Hypersensitivity","enrollment":54},{"nctId":"NCT01711684","phase":"PHASE1","title":"Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2012-10-16","conditions":"Neoplasm Metastasis, Melanoma","enrollment":6},{"nctId":"NCT03089775","phase":"PHASE1","title":"Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis","status":"COMPLETED","sponsor":"Fresh Tracks Therapeutics, Inc.","startDate":"2017-03-14","conditions":"Contact Dermatitis","enrollment":47},{"nctId":"NCT01978483","phase":"PHASE1","title":"Effect of RANKL Inhibition on UV-induced Immunosuppression","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2013-11","conditions":"Ultraviolet Rays, Immunosuppression, Hypersensitivity, Delayed","enrollment":31},{"nctId":"NCT01452594","phase":"","title":"Analysis of Diphenylcyclopropenone (DPCP) in Normals","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2011-10","conditions":"Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diphencyprone","DCP"],"phase":"marketed","status":"active","brandName":"diphenylcyclopropenone (DPCP)","genericName":"diphenylcyclopropenone (DPCP)","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diphenylcyclopropenone (DPCP) is a contact sensitizer that triggers a delayed-type hypersensitivity reaction to stimulate immune-mediated hair growth in alopecia. Used for Alopecia areata.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}